<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140542</url>
  </required_header>
  <id_info>
    <org_study_id>BY217/M2-401</org_study_id>
    <nct_id>NCT01140542</nct_id>
  </id_info>
  <brief_title>Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study</brief_title>
  <acronym>FORTUNA</acronym>
  <official_title>Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Phase IIb, Proof of Concept Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is a proof of concept study to confirm in a standardized manner the therapeutic
      efficacy of roflumilast in type 2 diabetes mellitus patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in HbA1c [percent] from baseline to the last study visit (Vlast)</measure>
    <time_frame>Baseline to last visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in HbA1c from baseline to each scheduled post-randomization visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to each scheduled post-randomization visit and Vlast in blood parameters</measure>
    <description>blood parameters: serum lipids (high-density-lipoprotein-cholesterol [HDL], low-density-lipoprotein-cholesterol [LDL], and triglycerides [TG]), fasting plasma glucose (FPG), fructosamine, glycerol, free fatty acids [FFA], plasma insulin, fasting pro-insulin, cholesterol, c-reactive protein (CRP), interleukin-6 (IL-6), TNF-α, intercellular adhesion molecule 1 (ICAM-1), E-selectin, plasminogen activator inhibitor 1 (PAI-1), adiponectin, and leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to each scheduled post-randomization visit and Vlast based on a 5-hour period post meal area under the curve (AUC) for FFA, glycerol, glucose, glucagons, insulin, and C-peptide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight, waist and hip circumference, waist to hip ratio, and body mass index (BMI) from baseline to each scheduled post-randomization visit and Vlast</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event (study withdrawal, time to study withdrawal due to an adverse event (AE) and time to lack of efficacy (LOE)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">487</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500µg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500µg, once daily</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  given written informed consent

          -  patients with diagnosis of type 2 diabetes according to American Diabetes Association
             (ADA) criteria and inadequately controlled on diet and exercise alone

          -  HbA1c at baseline: ≥7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine and
             Romania)

          -  BMI between ≥26 and ≤35 kg/m2

          -  willingness of patient to check his/her blood glucose with equipment provided by the
             sponsor during the treatment phase in case of hypo-/hyperglycemia episodes

          -  willingness to adhere to the physician's advise to comply with diet and exercise

        Main Exclusion Criteria:

          -  patients diagnosed with type 1 diabetes or diabetes secondary to pancreatitis or
             resection of pancreas

          -  patients diagnosed with hemoglobinopathies, hemolytic anemia or other diseases which
             interfere with HbA1c measurement

          -  non-euthyroid patients or patients with a non-controlled hypo- or hyperthyroidism

          -  reported gain or loss of more than 5 percent of body weight within the last 2 months
             prior to V0

          -  treatment with any diabetes medication prior to V0

          -  treatment with any weight-loss medication within 3 months prior to V0

          -  treatment with any not allowed medication or nutrition additives

          -  clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical evaluation (as assessed by the investigator)

          -  clinically significant cardiac abnormalities (diagnosed clinically, or by X-ray/ECG)
             that were not related to type 2 diabetes mellitus and that required further evaluation

          -  participation in a clinical study with study medication for weight loss or type 2
             diabetes

        Patients were randomized after 2 weeks of the baseline period, if the following criteria
        were fulfilled:

          -  judged to be clinically stable

          -  tablet compliance ≥80 percent and ≤125 percent

          -  HbA1c in the range of 7.5 percent to 8.5 percent (up to 9 percent in Mexico, Ukraine
             and Romania) tested at V0 by the central laboratory
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4496&amp;filename=BY217-M2-401-RDS-2009-01-14-.pdf</url>
    <description>BY217-M2-401-RDS-2009-01-14-.pdf</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2010</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

